Abstract
Multiple sclerosis is a multifactorial disease of the central nervous system characterized by an autoimmune reaction against myelin with consecutive neurodegeneration and associated neurological impairment. Until now more than ten medications received market authorization. Daclizumab is a monoclonal antibody directed against the IL-2 alpha subunit (CD25) which recently received market authorization for relapsing multiple sclerosis. We will review the potential mechanisms of action, pivotal clinical trial data, side effect profile and the significance for multiple sclerosis therapy.
| Translated title of the contribution | Evaluation of daclizumab for relapsing multiple sclerosis |
|---|---|
| Original language | German |
| Pages (from-to) | 715-719 |
| Number of pages | 5 |
| Journal | Internistische Praxis |
| Volume | 58 |
| Issue number | 4 |
| State | Published - 2018 |
| Externally published | Yes |
Keywords
- CD56 natural killer cells
- Daclizumab
- Disease modifying therapy
- IL-2
- Immunomodulatory therapy
- Relapsing multiple sclerosis